Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Funafuti Tech Report.
Press releases published on September 4, 2025
SIOS Technology Named Among the Best Places to Work in South Carolina for the Sixth Consecutive Year
GlobeNewswire
·
September 4, 2025
SAN MATEO, Calif. and COLUMBIA, S.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SIOS Technology Corp., a leading provider of application high availability (HA) and disaster recovery (DR) solutions, today announced that it has been named the 2025 Best Places to …
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire
·
September 4, 2025
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic …
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
GlobeNewswire
·
September 4, 2025
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a …
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with …
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
GlobeNewswire
·
September 4, 2025
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and …
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
GlobeNewswire
·
September 4, 2025
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM …
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
GlobeNewswire
·
September 4, 2025
THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of …
SEALSQ Accelerates Post-Quantum Readiness with Next-Generation TPMs Ahead of 2027 U.S. Government Deadline
GlobeNewswire
·
September 4, 2025
Geneva, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced …
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. …
ZenaTech to Highlight Progress on Drone as a Service and US Defense Business at Multiple Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), …
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
GlobeNewswire
·
September 4, 2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated …
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team …
24/7 Market News: TEN Holdings Poised for High-Growth with SaaS Expansion and M&A Potential, Says All-Star
GlobeNewswire
·
September 4, 2025
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Barry M. Sine, CFA, CMT, two-time Wall Street Journal All-Star …
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
GlobeNewswire
·
September 4, 2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced …
Arbe to Participate in Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
Tel Aviv, Israel, September 4, 2025 - Arbe Robotics Ltd. (Nasdaq: ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that members of Arbe’s management will be participating at the following investor conferences during …
U.S. EV Market Matures Despite Infrastructure Gaps and Consumer Hesitation
GlobeNewswire
·
September 4, 2025
HERE-SBD EV Index 2025 reveals U.S. entering early stages of large-scale EV deployment with gains across all four Index categories New consumer survey finds U.S. drivers most resistant to EV adoption compared to drivers in Europe, citing charging access as …
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, …
PathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and Primaa
GlobeNewswire
·
September 4, 2025
BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight Dx1 Image Management System (IMS), today announced new partnerships with three cutting-edge AI …
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
GlobeNewswire
·
September 4, 2025
CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief
GlobeNewswire
·
September 4, 2025
ROCKAWAY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its partnership with Greg Buttle, former New York Jets linebacker and NFL star, to help …